Transcutaneous Auricular Vagus Nerve Stimulation (taVNS) in Chronic Kidney Disease (CKD)
NCT ID: NCT06927024
Last Updated: 2025-12-31
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
RECRUITING
NA
30 participants
INTERVENTIONAL
2025-10-15
2029-01-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
SINGLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Active taVNS
Participants receive two weeks of 15-minute taVNS daily in the morning.
Active taVNS
Active taVNS delivered via the TENS Device 7000.
Sham taVNS
Participants receive two weeks of 15-minute sham intervention daily in the morning.
Sham taVNS
Sham taVNS delivered via the TENS Device 7000.
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Active taVNS
Active taVNS delivered via the TENS Device 7000.
Sham taVNS
Sham taVNS delivered via the TENS Device 7000.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of Chronic Kidney Disease (CKD) stage 3-5 \[estimated glomerular filtration rate \≤60 mL/min/1.73m2\]
* Receiving care at NYU Nephrology outpatient practice
* Able to provide informed consent
Exclusion Criteria
* Arrhythmias
* Implantable cardioverter-defibrillator (ICD) or pacemaker (PPM) precluding assessment of HRV (e.g., chronic atrial fibrillation)
* On maintenance dialysis (HD)
* Epilepsy
* Symptomatic bradycardia
* Presence of an implantable defibrillators
* Presence of a permanent pacemaker
* Unable to consent
* Incarcerated individuals
* Pregnant individuals
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
NIH
NYU Langone Health
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Qandeel Soomro, MD
Role: PRINCIPAL_INVESTIGATOR
NYU Langone Health
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
NYU Langone Health
New York, New York, United States
Countries
Review the countries where the study has at least one active or historical site.
Central Contacts
Reach out to these primary contacts for questions about participation or study logistics.
Facility Contacts
Find local site contact details for specific facilities participating in the trial.
Qandeel Soomro, MD
Role: primary
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
24-00756
Identifier Type: -
Identifier Source: org_study_id